Skip to main content
Medical information Clinical review pending

Genetic Testing

Oncopro Hereditary Cancer Risk Panel Screens 200 Genes Test

The Oncopro Hereditary Cancer Risk Panel screens 200 genes associated with increased cancer risk. This test is recommended for individuals with a significant family history of cancer to help assess risk and guide prevention strategies.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
10 mL (8 mL minimum) of whole blood collected in a Lavender Top (EDTA) tube.
Results
Confirm with the laboratory before booking.
Preparation
A completed Oncopro Hereditary Cancer Risk Clinical Information Form (Form 27) must be submitted with the sample. Confirm with the laboratory before booking.
Test priceKSh 65,520

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Oncopro Hereditary Cancer Risk Panel Screens 200 Genes Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Significant family history of cancer
  • ✓Multiple family members diagnosed with cancer
  • ✓Early onset of cancer in family members
  • ✓Known genetic mutations in the family
  • ✓Personal history suggestive of hereditary cancer syndrome
  • ✓Individuals seeking to understand their genetic cancer risk
02

In plain language

What this test helps you understand

Identifies inherited genetic mutations associated with an increased risk of developing various cancers. Helps assess individual cancer risk based on genetic factors. Informs personalized cancer prevention, screening, and management strategies. Provides information for family members regarding their potential risk.
The Oncopro Hereditary Cancer Risk Panel is a comprehensive genetic test designed to identify potential inherited predispositions to cancer. Using advanced Next Generation Sequencing (NGS) technology, this test analyzes 200 genes known to be associated with an increased risk of developing certain cancers. Understanding your genetic risk can empower you and your healthcare provider to make informed decisions about screening, prevention, and management. This test is particularly relevant for individuals with a strong family history of cancer. Results will indicate whether specific gene mutations associated with hereditary cancer syndromes have been detected. Discussing these results with a healthcare professional is crucial for understanding their implications for your health.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationA completed Oncopro Hereditary Cancer Risk Clinical Information Form (Form 27) must be submitted with the sample. Confirm with the laboratory before booking.
Sample10 mL (8 mL minimum) of whole blood collected in a Lavender Top (EDTA) tube.
MethodologyNext Generation Sequencing (NGS)
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test screens for specific mutations in the 200 genes analyzed. It may not detect all possible cancer-related genetic variations. A negative result does not completely eliminate cancer risk. Results should be interpreted in conjunction with personal and family medical history.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Individuals with a strong family history of cancer, multiple relatives with cancer, early-onset cancer in the family, or known genetic mutations should consider this test. Discuss with your doctor.
This panel screens for genes associated with various hereditary cancers, including breast, ovarian, colorectal, and others. Specific risks depend on the genes analyzed and mutations found.
The test requires a blood sample collected in a specific Lavender Top (EDTA) tube. Ensure the correct volume and tube type are used.
A positive result indicates the presence of a gene mutation associated with increased cancer risk. It's important to discuss this with your doctor to understand the implications and next steps.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
Turnaround time can vary. Please confirm the current estimated turnaround time with the laboratory before booking.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp